You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Intracranial Pressure Assessment and Screening System for Viral or Bacterial Infections (IPASS-VorBI)

    SBC: VIVONICS INC            Topic: CBD192005

    Pathogens reach the subarachnoid space (SAS) through the blood-stream, or from contiguous sites, and penetrate the blood-brain barrier though complex molecular and cellular mechanisms [1, 2]. For example, meningitis causes an imbalance between the water content of the brain parenchyma, CSF volume and cerebral blood flow thus resulting in a net increase of ICP [3]. Cerebral edema caused by inflamma ...

    SBIR Phase II 2021 Department of DefenseOffice for Chemical and Biological Defense
  2. Optimization of a broad-spectrum Ebolavirus cell entry inhibitor chemical series as a countermeasure for parental and aerosol routes of infection

    SBC: ARISAN THERAPEUTICS INC            Topic: CBD192006

    Ebolavirus species including Zaire (EBOV), Sudan (SUDV) and Bundibugyo (BDBV) are responsible for severe hemorrhagic fever outbreaks with high case fatalities in Africa [1,2]. Outbreaks of EBOV in the Democratic Republic of the Congo (DRC) as well as the 2014-2016 outbreak in West Africa highlight the danger that these zoonotic viruses pose through mucosal routes of infection and secondary human t ...

    SBIR Phase II 2021 Department of DefenseOffice for Chemical and Biological Defense
  3. Increasing Interoperability of Brain Morphometrics Using FHIR

    SBC: CORTICOMETRICS LLC            Topic: NIBIB

    PROJECT SUMMARY With the rise of artificial intelligence (AI) algorithms in medicine, radiologists have new tools at their disposal to quantitatively assess imaging data. However, in order to unlock this potential, data needs to be shared easily and effectively between all parts of the health information technology (IT) system. The goal of this project is to reduce data access barriers by developi ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Discovery of 12/15-lipoxygenase inhibitors to suppress neuroinflammation and slow disease progression in Alzheimer's disease

    SBC: ACUREX BIOSCIENCES CORP            Topic: NIA

    Shrader, William D. Abstract: Alzheimerandapos;s disease (AD) is the largest unmet medical need in the US and the only major cause of death that cannot be prevented, cured, or slowed. Arviat Pharmaceuticals, Inc. is developing oral small-molecule inhibitors of the 12/15-lipoxygenase (12/15-LO) enzyme family to reduce microglia driven neuroinflammation and, thereby, slow progression of AD. Inhibiti ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Wearable Vibration Device to Prevent Bone Loss in Postmenopausal Women

    SBC: BONE HEALTH TECHNOLOGIES, INC.            Topic: R

    Abstract Approximately 43 million Americans suffer from osteopenia, a highly common skeletal condition defined by accelerated bone loss. If bone loss is not mitigated, patients become osteoporotic and are at increased risk of bone fractures, particularly of the hips and spine. Such fractures decrease independent living, shorten life, and increase morbidity. Clinical guidelines for treating osteope ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Commercializing In-Home Supportive Technolgy for Dementia Caregivers

    SBC: PEOPLE POWER COMPANY            Topic: R

    AbstractCaring for a loved one with Alzheimer’s disease, related dementias, or mild cognitive impairment is a highly meaningful part of family life. However, the associated burden and strain can have adverse effects on caregivers including declines in mental and physical health, reduced well-being, and increased mortality. These effects can compromise care quality for people with dementia (PWD). ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Xenon gas treatment to modulate microglia in neurodegenerative diseases

    SBC: General Biophysics LLC            Topic: NIA

    Administrative Supplement Application PA-20-272 Xenon gas treatment to modulate microglia in neurodegenerative diseases (R41AG073059) ABSTRACT ABSTRACT FROM ORIGINAL APPLICATION Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays a significant ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a stem cell platform for the treatment of neurodegenerativemicrogliopathies

    SBC: Novoglia, Inc.            Topic: NINDS

    Project SummaryWe have developed a platform technology that uses induced human pluripotent stem cells (iPSCs) to generate genetically corrected microglia at scale and with high purity for transplantation. In this study, we will demonstrate the safety and therapeutic efficacy of our microglia transplantation technology using a mouse genetic model of adult-onset leukoencephalopathy with axonal spher ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Small molecule targeting an epigenetic regulator for the treatment of osteoarthritis

    SBC: DORIAN THERAPEUTICS, INC.            Topic: NIA

    The goal of the project is to develop a disease-modifying treatment for Osteoarthritis (OA) by targeting USP16, a chromatin modifier involved in regulation of senescence and stem cell self-renewal. The treatment will consist of an intra-articular injection of a small molecule inhibiting USP16 in patients with moderate OA. USP16 is a deubiquitinase (DUB) enzyme that removes ubiquitin from histone H ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical development of a novel therapeutic for Parkinson's disease

    SBC: SINOPIA BIOSCIENCES INC            Topic: 106

    Project Summary Parkinson’s Disease (PD) is the second most common neurodegenerative disorder, afflicting ~1 million Americans. Levodopa is the gold-standard symptomatic treatment for PD by elevating dopamine levels in the brain. Though the most effective treatment, prolonged levodopa use leads to 1) the debilitating side effect, levodopa-induced dyskinesia (LID), and 2) diminished levodopa effi ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government